Insider buying last 90 days
No open-market insider purchases were filed for DVA in the last 90 days.
From Form 4 filings, dated to when each was filed.
DaVita closed at $185.54 on 9 November 2026, -3% on the day. The price sits above both the 50-day ($182.69) and 200-day ($179.48) moving averages, inside a 52-week range of $101.00 to $247.49. The GekkoIndex reads 55.4, in the Neutral zone, down 0.7 points over five sessions. Gekko Fair Value is $216.85, so the price is 14.4% below it.
The next earnings report is due on 1 February 2027, 78 days away (after close). Over the last 8 reports the company beat the earnings estimate 7 times, with an average move of 12% across the report. Over the last 30 days there were 3 unusual options signals. Seasonally, the next 20 trading days from this point averaged +6.5% over the last 5 years, rising in 3 of them.
4 firms rate the stock: 2 buy, 1 hold and 1 sell, with a consensus target of $222.29. A typical daily move is about 4.3%, and a typical 20-day move about 5.6%. On the swing-trade checklist, 5 items read supportive and 0 read as a headwind.
A plain summary of the figures as of the Nov 9, 2026 close.
DaVita scores 4 supportive, 2 mixed and 0 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive2 mixed0 headwinds
Averages disagree
Close $174.56 sits between the 50-day ($182.66) and 200-day ($180.91) averages, or the averages disagree.
See the chart63.7, Accumulation
Reading 63.7 is in the Accumulation zone.
See the GekkoIndex25.6% below
Price is 25.6% below Gekko Fair Value (more than 5% below).
See fair valueLeans bullish
Last 30 days: 3 unusual options signals.
See smart moneyReports in 78 days
Next report Feb 1, 2027, 78 days away — outside a typical 20-trading-day hold.
See earnings+3.5% on average
From this point in the calendar, the next 20 trading days averaged +3.5% over 5 years, rising in 2 of them.
See seasonalityA description of current data, not a recommendation. How this page works
DaVita closed at $174.56 on Nov 13, 2026, +41.2% over the past year, inside a 52-week range of $101.00 to $247.49.
Use the left and right arrow keys to read daily values.
Put DVA on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
DaVita provides dialysis care for people living with chronic kidney failure, treating patients mainly through outpatient centers while also offering care in hospitals and in patients' homes. The company runs its own laboratories to handle routine testing for dialysis patients and other physician-ordered analyses for those with end-stage renal disease, and it is widely recognized for this combination of direct treatment and lab support.
Beyond patient care, DaVita provides administrative and management services to other outpatient dialysis facilities and runs chronic disease management programs, including risk-based and other integrated care arrangements for patients with kidney disease. Its offerings also include vascular access procedures, clinical research work, physician support services, and broader kidney care programs. Together these operations serve patients across a large network of outpatient centers in the United States and in other countries, along with acute dialysis and laboratory services delivered inside hospitals.
DaVita was founded in 1994 and is headquartered in Denver, Colorado. It previously operated under the name DaVita HealthCare Partners Inc. before adopting its current name in September 2016. Its shares are listed on the NYSE under the ticker DVA.
DaVita’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 63.7, in the Accumulation zone, up 12 points over five sessions.
Up 12 points over five sessions, from the Neutral zone.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 42 | +1.5% | +10.0% | ||
| Accumulation (current zone) | 210 | +1.2% | +4.4% | ||
| Neutral | 387 | −0.1% | −0.2% | ||
| Distribution | 56 | +1.9% | +4.5% | ||
| Selling | 7 | Too few readings yet | |||
Average DVA share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.0% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
DaVita trades 25.6% below Gekko Fair Value of $234.65, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what DaVita shares are worth, recalculated every trading day.
$234.65
Gekko Fair Value, Nov 14, 2026
25.6% Undervalued
At the end of Aug 2026 the price was 23.0% below the estimate.
No open-market insider purchases were filed for DaVita, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for DVA in the last 90 days.
From Form 4 filings, dated to when each was filed.
No trades in DVA were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
DaVita has been buying back its own shares.
From company filings.
3signals, 93% of the flagged premium in calls.
Latest: Bullish flow on Oct 30, $1.55M in unusual premium.
1of the funds Gekko tracks holds DVA.
DaVita reports on Feb 1, 2027, after the close (78 days away), and beat the EPS estimate in 7 of its last 8 reports.
Feb 1, 2027
Expected after the close, 78 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Oct 29, 2026 | $3.82 est $3.57 | $3.58B est $3.52B | +1.9% |
| Aug 4, 2026 | $4.02 est $4.01 | $3.55B est $3.50B | −19.3% |
| May 5, 2026 | $2.87 est $2.41 | $3.42B est $3.36B | +25.8% |
| Feb 2, 2026 | $3.40 est $3.24 | $3.62B est $3.51B | +23.2% |
| Oct 29, 2025 | $2.51 est $3.17 | $3.42B est $3.43B | −8.4% |
| Aug 5, 2025 | $2.95 est $2.70 | $3.38B est $3.44B | −8.4% |
| May 12, 2025 | $2.00 est $1.95 | $3.22B est $3.21B | +0.2% |
| Feb 13, 2025 | $2.24 est $2.14 | $3.29B est $3.27B | −8.5% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for DaVita is $222.29, +27.3% from the last close, from 4 firms rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 4 firms.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Nov 12 | UBS | $287 | +64.4% |
| Nov 2 | Barclays | $216 | +23.7% |
| Nov 2 | UBS | $287 | +64.4% |
| Nov 2 | TD Cowen | $228 | +30.6% |
| Oct 30 | Bank of America Securities | $180 | +3.1% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, DaVita averaged +3.5% across the last 5 years, rising in 2 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.5% | 2 of 5 |
| Next 10 trading days | −0.1% | 2 of 5 |
| Next 15 trading days | +2.2% | 3 of 5 |
| Next 20 trading days | +3.5% | 2 of 5 |
| Next 30 trading days | +2.5% | 3 of 5 |
For scale, DVA’s typical 20-trading-day move in either direction is about 5.6%.
DaVita’s market cap is $10.98B, with a P/E ratio of 13.2 and revenue of $14.17B over the last twelve months.
Coverage of DaVita this week reads negative: 2 positive, 1 neutral and 7 negative headlines.
DaVita’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LHLabcorp | Neutral | 8.5% above |
| GHGuardant Health | Accumulation | 16.4% below |
| SOLVSolventum | Neutral | 17.0% below |
| BTSGBrightSpring Health Services | Neutral | 11.0% above |
| EHCEncompass Health | Neutral | 14.7% above |
| ENSGEnsign | Neutral | 15.6% above |
A peer links to its own page where one exists.
DaVita’s market cap is $10.98B at the Nov 13, 2026 close of $174.56, with 62.90M shares outstanding. The shares trade on a P/E ratio of 13.2.
The consensus analyst 12-month price target for DaVita is $222.29, +27.3% from the last close. Of the 4 firms that rated the stock in the last 90 days, 2 rate it a buy, 1 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate DaVita is undervalued: the Nov 13, 2026 close of $174.56 is 25.6% below Gekko Fair Value of $234.65. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
DaVita is expected to report on Feb 1, 2027, after the market closes (78 days away). Analysts expect earnings of $4.14 per share on revenue of $3.65B. DaVita beat the earnings estimate in 7 of its last 8 reports, moving 12% on average across the report.
DaVita’s 52-week high is $247.49 and its 52-week low is $101.00; it closed at $174.56 on Nov 13, 2026, +41.2% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (gekkoindex, fair value, smart money and earnings risk), 2 as mixed (trend and seasonality). The checklist is a description of current data, not a recommendation.
Gekko flagged 3 unusual options signals in DaVita over the last 30 days, with $4.60M of flagged premium in calls and $350K in puts. The latest, bullish flow, was on Oct 30, 2026 with $1.55M in unusual premium. The signal-by-signal table is in Gekko.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.